Our findings are confirmatory of the individual trial findings for CIT versus chemotherapy and are consistent with NCCN and ESMO recommendations for first-line treatment of patients with NSCLC and high PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.